Exane Derivatives’s NeoGenomics NEO Stock Holding History

Exane Derivatives’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1.23K	Sell	151 -2,076	-93%	-$19.8K	﹤0.01%	486
2022 Q1	$27.1K	Sell	2,227 -1,533	-41%	-$32.3K	0.01%	634
2021 Q4	$128K	Buy	3,760 +277	+8%	+$10.8K	0.03%	414
2021 Q3	$168K	Sell	3,483 -576	-14%	-$26.7K	0.04%	430
2021 Q2	$183K	Sell	4,059 -1,321	-25%	-$58.5K	0.04%	432
2021 Q1	$259K	Sell	5,380 -2,273	-30%	-$118K	0.07%	254
2020 Q4	$412K	Buy	+7,653	New	+$346K	0.12%	194

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Exane Derivatives's NEO Position: Q2 2022 in Review

Exane Derivatives reduced its NeoGenomics (NEO) stake by 93% in Q2 2022, selling an estimated $19.8K and leaving 151 shares worth $1.23K. The position accounts for ﹤0.01% of the portfolio, ranked #486.

Exane Derivatives first reported a position in NEO in Q4 2020 and has held it in 7 quarters since. The position peaked at $412K in Q4 2020. 239 funds tracked by Wall St. Rank hold NEO as of Q2 2022.

Exane Derivatives held 151 shares of NeoGenomics worth $1.23K as of Q2 2022.
Exane Derivatives sold 2,076 NeoGenomics shares in Q2 2022, an estimated $19.8K.
NeoGenomics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #486 holding.
Exane Derivatives first reported a position in NeoGenomics in Q4 2020 and has held it in 7 quarters since.
Exane Derivatives's NeoGenomics position peaked at $412K in Q4 2020.
239 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.